27 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
23639540	89	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.	Vanderbilt University Medical Center
23130626	46	Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFß signaling.	Human Biomolecular Research Institute
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
15267232	65	Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.	Eli Lilly
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21376583	232	Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.	Amgen
20919678	109	Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factorß receptor I (TGFßRI).	Boehringer Ingelheim Pharma
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
16539403	78	Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.	Eli Lilly
31693351	473	Discovery of 4	TBA
32071685	40	Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF?R1 Inhibitor as an Immuno-oncology Agent.	Bristol-Myers Squibb Research & Development
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
30429955	44	Discovery of 4-Azaindole Inhibitors of TGF?RI as Immuno-oncology Agents.	Bristol-Myers Squibb Research and Development
30227946	58	Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.	National Center For Advancing Translational Sciences
29422332	51	Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGF?RI).	Bristol-Myers Squibb
9599243	4	Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.	Eli Lilly
7535424	29	Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylase release.	Tulane University
6149136	83	Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro.	Mayo Clinic
15293984	11	Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.	University of Michigan